Liu, D.; Kaufmann, G.F.; Breitmeyer, J.B.; Dickson, K.-A.; Marsh, D.J.; Ford, C.E.
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics 2022, 14, 837.
https://doi.org/10.3390/pharmaceutics14040837
AMA Style
Liu D, Kaufmann GF, Breitmeyer JB, Dickson K-A, Marsh DJ, Ford CE.
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022; 14(4):837.
https://doi.org/10.3390/pharmaceutics14040837
Chicago/Turabian Style
Liu, Dongli, Gunnar F. Kaufmann, James B. Breitmeyer, Kristie-Ann Dickson, Deborah J. Marsh, and Caroline E. Ford.
2022. "The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells" Pharmaceutics 14, no. 4: 837.
https://doi.org/10.3390/pharmaceutics14040837
APA Style
Liu, D., Kaufmann, G. F., Breitmeyer, J. B., Dickson, K.-A., Marsh, D. J., & Ford, C. E.
(2022). The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics, 14(4), 837.
https://doi.org/10.3390/pharmaceutics14040837